Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Gils

Showing results (151-160 of 162) with videos related to

Pageof 17
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 29, 2014
Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's diseaseDavid Drobne, Peter Bossuyt, Christine Breynaert, et al.
Annals of Internal Medicine|December 8, 2015
Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort StudyIsabelle Cleynen, Wouter Van Moerkercke, Thomas Billiet, et al.
Journal of Molecular Biology|March 22, 2017
Prediction and Reduction of the Aggregation of Monoclonal AntibodiesRob van der Kant, Anne R Karow-Zwick, Joost Van Durme, et al.
Gut|October 23, 2014
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's diseaseNiels Vande Casteele, Reena Khanna, Barrett G Levesque, et al.
Blood|July 5, 2003
Vasculin, a novel vascular protein differentially expressed in human atherogenesisAnn P J J Bijnens, Ann Gils, Barry Jutten, et al.
Journal of Crohn'S & Colitis|April 17, 2019
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort StudyClaire Liefferinckx, Bram Verstockt, Ann Gils, et al.
Nature Medicine|May 8, 2015
Corrigendum: PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactinKhalid Bajou, Stephanie Herkenne, Victor L Thijssen, et al.
Nature Medicine|June 16, 2014
PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactinKhalid Bajou, Stephanie Herkenne, Victor L Thijssen, et al.
Cancer Cell|April 20, 2013
Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signalingCorentin Herbert, Ulrich Schieborr, Krishna Saxena, et al.
Cancer Cell|August 2, 2016
Molecular Mechanism of SSR128129E, an Extracellularly Acting, Small-Molecule, Allosteric Inhibitor of FGF Receptor SignalingCorentin Herbert, Ulrich Schieborr, Krishna Saxena, et al.
Pageof 17

Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 29, 2014
Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's diseaseDavid Drobne, Peter Bossuyt, Christine Breynaert, et al.
Annals of Internal Medicine|December 8, 2015
Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort StudyIsabelle Cleynen, Wouter Van Moerkercke, Thomas Billiet, et al.
Journal of Molecular Biology|March 22, 2017
Prediction and Reduction of the Aggregation of Monoclonal AntibodiesRob van der Kant, Anne R Karow-Zwick, Joost Van Durme, et al.
Gut|October 23, 2014
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's diseaseNiels Vande Casteele, Reena Khanna, Barrett G Levesque, et al.
Blood|July 5, 2003
Vasculin, a novel vascular protein differentially expressed in human atherogenesisAnn P J J Bijnens, Ann Gils, Barry Jutten, et al.
Journal of Crohn'S & Colitis|April 17, 2019
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort StudyClaire Liefferinckx, Bram Verstockt, Ann Gils, et al.
Nature Medicine|May 8, 2015
Corrigendum: PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactinKhalid Bajou, Stephanie Herkenne, Victor L Thijssen, et al.
Nature Medicine|June 16, 2014
PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactinKhalid Bajou, Stephanie Herkenne, Victor L Thijssen, et al.
Cancer Cell|April 20, 2013
Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signalingCorentin Herbert, Ulrich Schieborr, Krishna Saxena, et al.
Cancer Cell|August 2, 2016
Molecular Mechanism of SSR128129E, an Extracellularly Acting, Small-Molecule, Allosteric Inhibitor of FGF Receptor SignalingCorentin Herbert, Ulrich Schieborr, Krishna Saxena, et al.
Pageof 17